Results 261 to 270 of about 105,678 (295)

Cardiovascular effects of selective cyclooxygenase-2 inhibitors

Expert Review of Cardiovascular Therapy, 2004
Selective cyclooxygenase-2 inhibitors represent a significant advance in the management of inflammatory disorders. They have similar efficacy to nonselective 'conventional' nonsteroidal anti-inflammatory drugs, but a superior gastrointestinal safety profile.
Henry, Krum, Danny, Liew, Juan, Aw, Steven, Haas   +3 more
openaire   +2 more sources

Hemicrania Continua Responds to Cyclooxygenase‐2 Inhibitors

Headache: The Journal of Head and Face Pain, 2002
Background.—Hemicrania continua is a primary headache disorder defined by its absolute responsiveness to indomethacin. We report the treatment response to two cyclooxygenase‐2 inhibitors, celecoxib and rofecoxib, in a series of patients with hemicrania continua.
Mario F P, Peres, Stephen D, Silberstein
openaire   +2 more sources

Selective Cyclooxygenase-2 Inhibitors

2004
Publisher Summary Cyclooxygenase (prostaglandin G/H synthase) catalyzes the conversion of arachidonic acid (AA) into prostaglandin H2 as the first committed step of prostaglandin biosynthesis. This enzyme is known to be the target of acetyl salicylic acid (ASA) and non-steroidal anti-inflammatory drugs (NSAIDs).
openaire   +1 more source

Gastroduodenal Safety of Cyclooxygenase-2 Inhibitors

Current Pharmaceutical Design, 2003
Cyclooxygenase-1 (COX-1) derived eicosanoids promote gastroprotective mucosal defenses and induce platelet aggregation. By sparing COX-1, COX-2 specific inhibitors provide effective anti-inflammatory and analgesic activity while substantially reducing the risk of peptic ulcer disease and GI bleeding compared to dual COX inhibitors (traditional NSAIDs).
openaire   +2 more sources

Selective inhibitors of cyclooxygenase-2

Expert Opinion on Therapeutic Patents, 1997
Prostaglandins (PGs) produced by the inducible enzyme cyclooxygenase-2 (COX-2) are important mediators of pain and inflammation. In animals, selective inhibitors of COX-2 have been shown to be anti-inflammatory without typical non-steroidal anti-inflammatory drug (NSAID) side-effects. Research directed towards the identification of potent and selective
openaire   +1 more source

CYCLOOXYGENASE-2 INHIBITORS

Gastroenterology Clinics of North America, 1996
Jaime L. Masferrer, Peter C. Isakson, Karen Seibert   +2 more
openaire   +1 more source

[Coxibs: cyclooxygenase-2 inhibitors].

Wiener klinische Wochenschrift, 2001
The oxygenating enzyme cyclooxygenase (COX) catalysis the conversion of arachidonic acid to proinflammatory prostaglandins. For many years it was thought that COX is a single enzyme that is present constitutively in most tissues. But in the late 80ies COX activity was found to be increased in inflammatory states with cytokines and bacterial ...
openaire   +1 more source

[Cyclooxygenase-2 and cyclooxygenase-2 inhibitors in prostate cancer].

Zhonghua nan ke xue = National journal of andrology, 2009
Cyclooxygenase-2 (Cox-2) is over-expressed in prostate cancer (PCa) and involved in its development and progression by facilitating inflammatory response, reducing cell apoptosis, increasing angiogenesis and damaging DNA oxidation. Selective Cox-2 inhibitors suppress PCa growth through various channels and therefore have a promising application value ...
Song, Xu, Jian-Ping, Gao, Wen-Quan, Zhou
openaire   +1 more source

Integrative oncology: Addressing the global challenges of cancer prevention and treatment

Ca-A Cancer Journal for Clinicians, 2022
Jun J Mao,, Msce, Lorenzo Cohen, Karen M Mustian   +2 more
exaly  

Correction: Cyclooxygenase-2 Inhibitors

Annals of Pharmacotherapy, 1999
Barbara Kaplan-Machlis, Barbara Storyk Klostermeyer   +1 more
openaire   +1 more source